Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic …
F Ge, Z Huo, X Cai, Q Hu, W Chen, G Lin… - JAMA network …, 2022 - jamanetwork.com
Importance A considerable number of clinical trials of neoadjuvant immunotherapy for
patients with resectable esophageal cancer are emerging. However, systematic evaluations …
patients with resectable esophageal cancer are emerging. However, systematic evaluations …
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma
Despite curative-intent treatment, most patients with locally advanced esophageal cancer
will experience disease recurrence or locoregional progression, highlighting the need for …
will experience disease recurrence or locoregional progression, highlighting the need for …
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT …
Z Lu, J Wang, Y Shu, L Liu, L Kong, L Yang, B Wang… - Bmj, 2022 - bmj.com
Objective To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin
plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally …
plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally …
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
T Kojima, MA Shah, K Muro, E Francois… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open …
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open …
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3 …
K Kato, BC Cho, M Takahashi, M Okada, CY Lin… - The Lancet …, 2019 - thelancet.com
Background Chemotherapy for patients with advanced oesophageal squamous cell
carcinoma offers poor long-term survival prospects. We report the final analysis from our …
carcinoma offers poor long-term survival prospects. We report the final analysis from our …
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo …
Background First-line therapy for advanced oesophageal cancer is currently limited to
fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour …
fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour …
Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from …
M Moehler, M Dvorkin, N Boku, M Özgüroğlu… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE The role of maintenance therapy for gastric (GC) or gastroesophageal junction
cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD …
cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD …
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized …
L Shen, K Kato, SB Kim, JA Ajani, K Zhao… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE Patients with advanced or metastatic esophageal squamous cell carcinoma
(ESCC) have poor prognosis. For these patients, treatment options are limited after first-line …
(ESCC) have poor prognosis. For these patients, treatment options are limited after first-line …
[HTML][HTML] Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by …
K Muro, E Van Cutsem, Y Narita, G Pentheroudakis… - Annals of …, 2019 - Elsevier
The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of gastric cancer (GC) was …
Practice Guidelines for the diagnosis, treatment and follow-up of gastric cancer (GC) was …